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Objective(s): An increase in nitric oxide (NO) production has been reported in cirrhotic 
cardiomyopathy and, portal hypertension. Since minocycline has been shown to inhibit NO 
overproduction, we aimed to examine its role in a rat model of CCl4-induced cirrhotic cardiovascular 
complications.  
Materials and Methods: Portal pressure and inotropic responsiveness of isolated papillary muscles to 
isoproterenol were measured in cirrhotic rats, following minocycline (50 mg/kg/day for 8 weeks) 
treatment. Moreover, isolated papillary muscles were incubated with nonselective and selective nitric 
oxide synthase (NOS) inhibitors, N (ω)-nitro-L-arginine methyl ester (L-NAME) and aminoguanidine 
(AG) respectively, in an organ bath. Ventricular expression and localization of inducible NOS (iNOS), 
tumor necrosis factor-alpha (TNF-α) and serum nitrite concentration were evaluated. 
Results: We found a decreased portal hypertension in minocycline-treated cirrhotic rats. Cirrhosis 
decreased contractility in response to isoproterenol stimulation, which was significantly attenuated by 
minocycline. Incubation with either L-NAME or AG reversed the impaired contractility in cirrhotic rats. 
Furthermore, minocycline decreased iNOS expression and localization in cardiomyocytes. A drop in 
serum nitrite and cardiac TNF-α level were also observed in cirrhotic rat that were treated by 
minocycline. 
Conclusion: The results suggest that minocycline may improve impaired cardiac contractility and 
hyperdynamic state in cirrhotic rats, and this effect could be mediated by NO-dependent mechanism. 
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Introduction 
“Cirrhotic cardiomyopathy” is associated with 
abnormalities of heart structure and its           
function (1, 2). The main clinical outcome of cirrhotic 
cardiomyopathy include decrement of systolic 
contractility, altered diastolic relaxation in response 
to physiologic and pharmacological agents, abnormal 
prolonged QT interval, and hyperdynamic state         
in cirrhotic patients (3, 4). Moreover, evidences      
have shown a correlation between cirrhotic    
cardiomyopathy and portal hypertension (1, 5). The 
impaired contractile responsiveness to isoproterenol 
(β-adrenergic receptor agonist) stimulation is also 
resulted from examination of cirrhotic rats (6). Body     
of evidences has indicated that several main
 mechanisms underlying the development of cirrhotic 
cardiomyopathy, such as activation of nitric oxide 
signaling pathway (7). Towards the end, nitric oxide 
synthase (NOS) inhibitors have been declared to 
attenuate the development of cardiomyocyte 
hypertrophy (8, 9). Nitric oxide (NO) pathway has been 
determined to be involved in abnormal cardiac 
contractility in response to β-adrenergic receptor 
agonists (7, 10). Van Obbergh et al (1996) have 
revealed the involvement of NO pathway in the 
decreased ventricular contractility profound in 
cirrhotic cardiomyopathy (6). Evidences have shown 
that the systemic NO overproduction induced by iNOS 
stimulation cause the negative inotropic effect.           
This seems to be modulated by cytokines such as the       
TNF-α and IL-1β, leading to cardiovascular 
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dysfunction and hyperdynamic circulation in 
cirrhosis (8, 11). Inhibition of NO synthesis in 
cardiomyocytes by iNOS blockade may play a critical 
role in the improvement of impaired contractility in 
cirrhotic patients. Therefore, we decided to utilize an 
iNOS inhibitor, like minocycline, in cirrhotic 
cardiomyopathy. 
Minocycline (7-dimethylamino-6-desoxytetracyc-
line), a semi-synthetic antibiotic with high therapeutic 
potential, is typically used as broad-spectrum antibiotic 
(12, 13). Minocycline has extensively investigated as 
anti-apoptotic, antioxidant, as well as possible 
cytoprotective agent (14-16). Previous studies have 
clarified that minocycline exerts these effects by 
regulating the activity of inflammatory mediators, 
including NO, TNF-α, IL-1β, IL6, scavengers of reactive 
oxygen species (ROS) (17-19). Minocycline has a 
potential protective effect on cardiomyocytes against 
ischemic injury by decreasing myocardial oxidative 
stress and matrix metalloproteinase (MMP), and 
inhibiting poly (ADP-ribose) polymerase-1 activity (20-
22). It has been shown that minocycline in pilot study is 
well torelated and effective in patients with chronic 
cholestatic liver disease, but this property has not been 
reported for any other tetracyclines (23). Furthermore, 
NOS inhibitors cannot be used for long time in the 
treatment of a control of chronic cardiovascular 
complications in clinic. However, moinocycline is void 
of such side effects.  
In the current study, we aimed to evaluate the 
cardioprotective effects of minocycline in cardiac 
inotropic disorders in response to β-adrenoceptor 
stimulation and hyperdynamic state in a rat model of 
CCl4-induced cirrhotic cardiomyopathy, considering the 
involvement of nitric oxide pathway. 
 
Materials and Methods 
Ethics statement 
Animal care and procedures performed during this 
study were approved by Animal Ethics Committee of 
Tehran University of Medical Sciences as well as Animal 
Care Guidelines Published by the Department of 
Pharmacology, School of Medicine, Tehran University of 
Medical Sciences. 
 
Animal’s manipulation 
Adult male Wistar rats weighing 100-130 g were 
obtained from Animal house of Experimental Medicine 
Research Center of Tehran University of Medical 
Sciences. Four rats per cage were housed with                        
ad libitum access to normal rodent chow and water, 
under standard room temperature (22±2 °C) on a 12-hr 
light/dark cycle.  
 
Chemicals and reagents 
The following agents were used in our research 
study: minocycline hydrochloride, tetracycline 
hydrochloride, isoproterenol hydrochloride, N(ω)-
nitro-L-arginine methyl ester (L-NAME), a non-    
specific NOS inhibitor; and aminoguanidine (AG),             
a specific iNOS inhibitor (Sigma-Aldrich, St. Louis, MO, 
USA), carbon tetrachloride (Merck, Germany), TNF-α 
assay kit (Biosource, Camarillo, CA), polyclonal                    
rabbit   anti-iNOS antibody (orb26708) and horseradish 
peroxidase (HRP)-conjugated anti-rabbit Immuno- 
globulin G antibody (Biorbyt Co Ltd., UK).  
 
Drug administration and experimental protocol 
Liver cirrhosis was induced in animals through 
intraperitoneally (IP) injections of 0.4 g/kg of CCl4. A 
solution of 1:6 of CCl4 in mineral oil was injected to the 
animals 3 times a week for 8 weeks up to ascites 
appearance (24). All rats were randomly divided into 
five experimental groups that consist of age-and 
weight-matched rats. Each group was containing 10 
animals. Group 1 only received drinking water and 
served as un-treated controls. Group 2 received CCl4 
(0.4 g/kg; 3 times a week through experimental 
period). Group 3 received minocycline hydrochloride 
(50 mg/kg/d), freshly dissolved in normal saline and 
was administered orally in drinking water in a constant 
volume of 14 ml/100 g body weight for the period of 8-
weeks (14, 22). Group 4 and 5 received the co-
administration of CCl4 with minocycline hydrochloride 
(50 mg/kg/d) and tetracycline hydrochloride (50 
mg/kg/d) respectively, in drinking water for 8 weeks. 
In addition, in order to evaluate the role of the NO 
pathway in the cardio protective effects of minocycline 
against CCl4-indiuced cirrhotic cardiomyopathy, The 
papillary muscles of the CCl4 and CCl4+minocycline 
groups were incubated with N (ω)-nitro-L-arginine 
methyl ester (L-NAME), a nonselective NO synthase 
inhibitor, and aminoguanidine (AG), a selective iNOS 
inhibitor, in an organ bath, 40 min before stimulation 
with cumulative concentration of isoproterenol. 
 
Sample collection 
Twenty four hours after end of the treatment 
protocol, rats were anesthetized by sodium thiopental 
(50 mg/kg; body weight). After recording ECG and 
collecting heart blood, liver and ventricular heart 
muscles were excised. Liver specimens were sectioned 
and stained with hematoxylin and eosin (H&E) reagent. 
Light microscopy of stained liver sections was done for 
establishment and induction of cirrhosis in rats (25). A 
small piece of left ventricular muscle was snap frozen in 
liquid nitrogen and stored at -70 °C for biochemical 
assay. Sections from the left ventricular muscle of each 
rat were prepared in order to histological evaluation 
and kept in 10% buffered formalin.  
 
Electrocardiography (ECG) 
ECG was recorded after the 8-week period before 
the excision of hearts. ECG was recorded for 15 min in 
rats underwent light anesthesia. Needle electrodes 
attached to a bioamplifier (ADI Instruments, spain) 
were inserted under the skin for the limb lead at 
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position II. For each ECG tracing, QT intervals were 
assessed. The signals were digitized at a sampling rate 
of 10 kHz by a Powerlab system and were exhibited 
using Lab Chart 7 software (ADInstrument, Australia). 
The Q-T intervals, presented as corrected Q-T (QTc), 
were calculated in a 5 min ECG. The QTc was obtained 
using Bazett’s formula (QTc = QT/ √R-R) (26). 
 
Left ventricular papillary muscle contractile study 
After ECG recording, Left ventricular papillary 
muscles were excised and isolated in a cold oxygenated 
physiological salt solution (PSS) aerated with 95% O2 
and 5% CO2. physiological salt solution contains the 
following in mmol/l: NaCl, 112; KCl, 5; CaCl2, 1.8; MgCl2, 
1; NaH2PO4, 0.5; KH2PO4, 0.5; NaHCO3, 25; glucose, 10; 
and EDTA, 0.004 (pH=7.4) (27). Papillary muscles were 
attached vertically to an isometric force transducer, 
under a tension of 500 mg in order to get maximum 
contractile force. The papillary muscles were 
equilibrated in a 25 ml glass chamber in an organ bath 
(Grass 88 Stimulator; Grass Instruments, MA, 
PowerLab, USA) for 90 min before the assessment of 
any drugs were used. The temperature of the bathing 
buffer was 33 °C. After equilibration, the muscles were 
subjected to electrical-field stimulation at 1 Hz and 30 
V, which is about 20% higher than the threshold to 
record the contractile force. Basal contractility was 
defined as the stable baseline contractile force of 
papillary muscles before the addition of the stimulating 
agents. To assess papillary muscle responsiveness to 
isoproterenol, the papillary muscles were stimulated by 
cumulative concentrations of isoproterenol (10−10 to 
10−5 M) to obtain a β-adrenoceptor concentration–
response curve. Maximal effect (Rmax) was defined as 
the contractile force after addition of the highest 
concentration of isoproterenol (10−5 M). For each 
concentration of isoproterenol, the increase in recorded 
contractile force was expressed as a percentage of the 
basal contraction (8). The aims of these studies were to 
explain whether selective and non-selective NOS 
inhibitors, AG and L-NAME respectively, added to the 
minocycline treated cirrhotic animals have additional 
effect on papillary muscle contractility and weather this 
effect is mediated by NO. For these studies, in some 
experimental groups, concentration response curves 
were constructed, 40 min after the papillary muscles 
were incubated with L-NAME at a concentration of 10−4 
M and AG (10−5 M), before the administration of 
isoproterenol. All doses of the drugs were selected 
based on pre-examination pilot studies. 
 
Measurement of intrasplenic pulp Pressure (ISPP) 
Splenic pulp pressure was measured as an index for 
portal pressure. Under an intraperitoneal injection of 
sodium thiopental anesthesia (50 mg/kg; body weight) 
rats underwent laparatomy and the spleen was 
exposed by retraction on the perisplenic fat. 
Intrasplenic pressure was measured by a PE tube 20 
gauge needle, inserted into the splenic parenchyma. 
The needle was connected to a pressure transducer 
that was linked to a Powerlab system (ADInstruments, 
Australia). Splenic pulp pressure was calibrated using a 
straight tube filled with saline solution and is expressed 
in mm H2O (28). 
 
Measurement of plasma nitrite concentration 
The levels of nitrite/nitrate, as indicators of NO 
production, in plasma samples were measured using 
Griess reagent (29). At the end of the experiment, blood 
samples collected from the animals in different groups 
were centrifuged at 21,925 g for 1.5–3 hr at 4 °C, 
through a 30 kDa molecular weight filter (Centricon 
Millipore, Bedford, MA, USA). Briefly, after removing 
substances layer, the samples were loaded in a 96-well 
microtiter plate (100 µl). Saturated solution of 100 µl of 
vanadium (III) chloride (VCl3) was added to the wells 
followed by the Griess reagent (100 µl each). The plates 
were measured using an ELISA standard plate reader at 
540 nm, followed by incubation at 37 °C for 30 min. The 
value obtained represented the amount of plasma 
nitrite/nitrate. Results are expressed as micromoles.  
 
Immunohistochemistry 
For immunohistochemical examination, the remov-ed 
left ventricle samples were immediately fixed in ice-cold 
freshly prepared 10% formalin and then the heart pieces 
were embedded in paraffin. The section blocks were cut 
and stored for immunohistochemistry. After 
deparaffinizing, 10 μm sections of the left ventricle muscle, 
in xylene and rehydrating in specific decreasing 
concentrations of ethanol and treated with 3% hydrogen 
peroxide in methyl alcohol for 5 min to block endogenous 
peroxidases activity. Immunohisto chemical staining 
based on the Avidin-Biotin peroxidase method. Human 
tonsil tissue was used as positive control and reaction 
with polyclonal rabbit anti-iNOS (1:2000 dilution) 
antibody for 1 hr at room temperature followed by 
incubation with the secondary HRP-conjugated rabbit 
anti-rabbit immunoglobulin G antibody (1:2000 
dilution) was done for 30 min at room temperature. 
After washing, the sections were successively treated 
with Tris buffer (pH 7.4) for three times. The sections 
were incubated with diaminobenzidine-hydrogen 
peroxide solution for 10 min and with 5% CuSO4 for 5 
min, and ultimately counterstained with hematoxylin-
eosin; Quantification of iNOS positive cells was 
performed by obtaining brown-colored precipitation of 
cells per high power field (20×) under light microscopy.  
 
Ventricular TNF-α quantification  
To measure tissue TNF-α, an ELISA available kit was 
used. The left ventricular samples were homogenized    
in ice-cold phosphate-buffered saline (PBS) and 
centrifuged at 14,200 g for 30 min. 50 μl of the samples 
and standard (bovine serum albumin) were pipetted 
into a 96-well plate precoated with rat TNF-α specific 
antibody. Following addition of biotinylated anti–TNF-α 
solution (50 μl) to each well plate and incubated for 90 
Minocycline attenuates CCl4-induced cardiomyopathy                                                                                                        Mousavi et al 
 
Iran J Basic Med Sci, Vol. 19, No.11, Nov 2016  
 
 
1225 
min at room temperature. The wells were washed for 4 
times with wash buffer. Then, 100 μl of streptavidin-
peroxidase was added to each well, and incubated for 
45 min at room temperature and repeatedly washing 
process for 4 times with PBS. Subsequently, exposed to 
100 μl of stabilized chromogen and incubated for 20 
min. Finally, 100 μl stop solution was added to each 
well for spectrophotometrically analysis at λ=450 nm 
(8). 
 
Western blot analysis 
Western blot analysis was performed using isolated 
left ventricle tissues. Briefly, left ventricle samples were 
homogenized in buffer (20 mmol/l Tris-HCl (pH 7.2), 
0.2 mmol/l phenylmethylsulfonyl fluoride, and 1 mM 
dithiothreitol) with homogenizer. The homogenate was 
centrifuged at 40,000 g and resuspended in Tris buffer 
containing proteinase inhibitor. 40 μg of the denatured 
protein samples were loaded and separated on sodium 
dodecyl sulfate-10% polyacrylamide gel (SDS-PAGE) by 
electrophoresis. Then, proteins were transferred to 
PVDF membrane at 4 °C by wet electroblotting for 2 hr. 
The consequence blots were blocked at room tempera- 
ture with 3% skimmed milk in 0.1% Tween Tris-
buffered saline buffer (TBS-T) (pH 7.5) for 1 hr. The 
membranes were subsequently washed with TBS-T for 
3 times, and incubated overnight at 4 °C with polyclonal 
rabbit anti-iNOS primary antibody (1:1000 dilution). 
Those exposed to horseradish peroxidase-conjugated 
anti-rabbit secondary antibody (1:20000 dilution). 
Finally, detection of blots was performed with 
enhanced chemiluminescence (ECL Western blot kit, 
Amersham) method (30). The intensity expression of 
iNOS protein was semi-quantified measured using 
ImageJ softwar (National Institutes of Health, Bethesda, 
MD) defining as the iNOS protein densitometric ratio 
(%). 
 
Statistical analysis 
The results are expressed as mean±SEM. Statistical 
evaluation of the data was performed with an analysis 
of variance (one-way ANOVA), followed by Tukey's 
post test in the case of 3 or more experimental groups. 
To examine the comparison between 2 groups, 
Student’s t-test was used. For evaluation of two 
variables (cirrhosis vs. control and other treatment 
groups) analysis was performed via two-way ANOVA 
followed by Bonferroni post test. Statistical analyses 
were calculated by GraphPad Prism software (version 
5.0, GraphPad Software, Inc., San Diego, CA, USA).           
A P-value less than 0.05 were considered statistically 
significant. 
 
Results  
All animals treated with CCl4 developed cirrhosis 
symptoms such as weight loss, jaundice, brown urine, 
ascites, stiffness of the liver and significant increase      
in spleen weight (1.62±0.13 vs. 2.86±0.61 g in         
control vs. CCl4-induced cirrhotic rats, ***P<0.001) 
contributing to enhancement of portal hypertension. 
Liver damage was confirmed with microscopic 
evaluation by H&E staining of liver tissues sampled 
from cirrhotic rats. The analysis revealed regenerative 
nodules of hepatocytes, extensive focal hepatocellular 
necrosis and bridging fibrosis between portal regions 
as shown in Figure 1. 
 
Evaluation of ECG parameters 
The influence of exposure to CCl4 and treatment 
with minocycline on ECG parameters is shown in Figure 
2. QTc intervals were assessed in control, CCl4 and 
minocycline-treated groups. Significant prolongation in 
QTc intervals were observed in CCl4-induced cirrhotic 
rats compared to control rats (P<0.001). Moreover, the 
prolonged QTc interval in cirrhotic rats was normalized 
by minocycline (50 mg/kg) (P<0.05). 
 
Effect of minocycline on the intrasplenic pulp 
pressure 
Intrasplenic pulp pressure was measured and used 
as an index of portal pressure. Significant differences in 
portal pressure were observed between control, CCl4-
induced cirrhotic, minocycline and tetracycline-treated 
cirrhotic rats (P<0.001; Figure 3). Portal pressure was 
gradually decreased after treatment of CCl4-induced 
cirrhotic rats with minocycline (P<0.05) compared to 
CCl4-induced cirrhotic rats, as shown in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Histological changes in liver tissue of CCl4-induced cirrhotic 
rats (H&E; magnification ×100 and ×400). (A) Focal hepatocellular 
necrosis and apoptotic cells are clearly seen (B) fatty degeneration and 
patchy inflammatory cells infiltration are observed 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison between QT intervals (QTc) of different 
experimental groups. Values are expressed as mean±SEM; n=6 for 
each group. ***P<0.001 and * P<0.05 compared to control group; 
#P<0.05 compared to CCl4-induced cirrhotic rats 
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Figure 3. Effect of minocycline on intrasplenic pulp pressure (ISPP) of 
rats in different experimental groups. Values are expressed as 
mean±SEM; n=6 in each group. A significant reduction was observed 
in ISPP in the CCl4+minocycline group. Also, ISPP significantly 
decreased in minocycline group. ***P<0.001 compared to control 
group. #P<0.05 compared to CCl4-induced cirrhotic rats. $$P<0.01 
compared to minocycline group 
 
However, treatment of cirrhotic rat with 
tetracycline failed to decrease the portal pressure in 
comparison with CCl4-induced cirrhotic rats. 
Furthermore, we observed a significant increase in 
portal pressure of rats treated with CCl4+minocycline 
in comparison with the rats received minocycline 
(P<0.01; Figure 3). 
 
Effects of minocycline and NOS Inhibitors on 
papillary muscle contractility 
The effect of minocycline HCl on cardiac 
contractility was examined. Baseline isoproterenol-
stimulated papillary muscle contractile force was 
significantly reduced in CCl4-induced cirrhotic rats 
compared to control group (74.56%±9.78% vs. 
117.41%±8.55%, P<0.001, for each variable). The 
maximum response (Rmax) to isoproterenol 
stimulation was achieved at 10−5 M. Also, the 
isoproterenol concentrations inducing half-maximal 
response (EC50) were −5.7±1.06 vs. −6.1±1.1 in the 
CCl4-induced cirrhotic and control group, 
respectively (Figure 4A). However, the Rmax of 
contractile force responsiveness to isoproterenol in 
minocycline-treated rats was not significantly 
different compared to control group (Figure 4B). 
A significant elevation of Rmax in the resulted 
concentration–response curve was observed in the 
CCl4+minocycline group compared to CCl4-induced 
cirrhotic rats (Figure 4C). Although treatment with 
minocycline normalized the basal contractile 
abnormalities in response to isoproterenol (P<0.01, 
for each variable) in the cirrhotic rats, tetracycline 
showed no significant change of responsiveness to 
isoproterenol in cirrhotic rats (Figure 4C). These 
data demonstrated that minocycline improves the 
maximal contractile force (Rmax) in response to 
isoproterenol stimulation in cirrhotic rats. 
On the other hand, when the cirrhotic papillary 
muscles were incubated with L-NAME, no significant 
difference in contractile response to isoproterenol 
stimulation was demonstrated. In contrast, when the 
papillary muscles from minocycline-treated cirrhotic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cumulative concentration-response curve for 
isoproterenol in left ventricular papillary muscles isolated from 
control, CCl4-induced cirrhotic and minocycline-treated rats. (A) The 
basal contractile force was significantly reduced in CCl4-induced 
cirrhotic rats compared to control group. Maximal response (Rmax) 
for CCl4-induced cirrhotic rats was significantly lower than controls. 
Also, a right-ward shift of the concentration-response curve for 
isopreterenol was observed in CCl4-induced cirrhotic rats vs. 
controls. ***P<0.001 compared to control group. (B) No significant 
differences were observed in comparison between control and 
minocycline-treated groups (n=6 in each group). (C) Cumulative 
concentration-response curve for isoproterenol in left ventricular 
papillary muscles isolated from CCl4, CCl4+minocycline and 
CCl4+tetracycline groups: Treatment with minocycline (50 mg/kg) 
normalized the basal contractile abnormalities in CCl4-induced 
cirrhotic rats. Contractility was significantly elevated in 
CCl4+minocycline group compared to CCl4-induced cirrhotic rats 
(**P<0.01). Treatment with tetracycline (50 mg/kg) showed no 
significant changes of responsiveness to isoproterenol stimulation in 
CCl4-induced cirrhotic rats (n=6 in each group) 
 
rats were incubated with L-NAME, contractile response 
to 10-5 M and 10-6 M of isoproterenol stimulation was 
significantly increased (P<0.001, Figure. 5A). When the 
papillary muscles from cirrhotic rats incubated with AG 
contractile force increased significantly (P<0.05). In 
addition, incubation with AG in minocycline-treated 
cirrhotic rats reversed the reduced contractile response 
to 10-5 M (P<0.001) and 10-6M (P<0.05) of isoproterenol 
stimulation compared to CCl4-induced cirrhotic rats 
(Figure 5B). The results showed that Rmax of papillary 
muscles isolated from CCl4-induced cirrhotic rats 
(74.56%±9.78%) was significantly different from            
the two other groups (CCl4+minocycline+L-NAME and 
CCl4+ minocycline+AG; Rmax 97.21%±8.4% and 
99.82%±7.8%, respectively). Furthermore, both                    
L-NAME and AG exerted a positive effect on papillary 
muscle contractility in CCl4-induced cirrhotic rats 
treated with minocycline (Figures 5A, B).  
 
Effects of minocycline treatment on plasma nitrite 
and Cardiac TNF-α levels 
The plasma concentration of nitrite and TNF-α level 
in cardiac tissue are presented in Table 1. TNF-α levels 
in cardiac homogenates showed a significant increase 
in CCl4 and CCl4+tetracycline groups compared               
to control group (P<0.001). The results demonstrated a  
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Figure 5. (A) Cumulative concentration-response curve for 
isoproterenol in left ventricular papillary muscles isolated from CCl4 
and CCl4+minocycline groups after incubation with L-NAME (10-4 M). 
Contractility was significantly increased in CCl4+minocycline+L-NAME 
group compared to CCl4-induced cirrhotic rats in response to 10-5 M 
(*** P<0.001) and 10-6 M (### P<0.001) of isoproterenol (n=6 in each 
group). **P<0.01 CCl4+minocycline group vs CCl4-induced cirrhotic 
rats. (B) Cumulative concentration-response curve for isoproterenol   
in left ventricular papillary muscles isolated from CCl4 and 
CCl4+minocycline groups after incubation with AG (10-5 M). 
Contractility was significantly increased in CCl4+AG group compared 
to CCl4-induced cirrhotic rats in response to 10-5 M of isoproterenol 
(*P<0.05). Also, a significant increase in contractility response was 
observed in CCl4+minocycline+AG group compared to CCl4-induced 
cirrhotic rats in response to 10-5 M (*** P<0.001) and 10-6 M (# P<0.05) 
of isoproterenol (n=6 in each group).n**P<0.01 CCl4+minocycline 
group vs CCl4-induced cirrhotic rats 
 
significant decrease of ventricular levels of TNF-α in 
cirrhotic animals treated with minocycline compared to 
CCl4-induced cirrhotic rats (P<0.01). Plasma 
concentration of nitrite in CCl4-induced cirrhotic rats 
was significantly higher than that in the control group 
(P<0.001). Also, our data showed that the increased 
plasma level of nitrite can be reduced by 8-week 
administration of minocycline to cirrhotic rats (P<0.01). 
In contrast, treatment of tetracycline in cirrhotic rats 
exerted no significant effect on plasma nitrite and 
ventricular level of TNF-α compared to CCl4-induced 
cirrhotic rats. 
Plasma concentration of nitrite in CCl4-induced 
cirrhotic rats was significantly higher than that in the 
control group (P<0.001). Also, our data showed that the 
increased plasma level of nitrite can be reduced by        
8-week administration of minocycline to cirrhotic rats 
(P<0.01). In contrast, treatment of tetracycline in 
cirrhotic rats exerted no significant effect on plasma 
nitrite and ventricular level of TNF-α compared to CCl4-
induced cirrhotic rats. 
 
Ventricular iNOS protein expression  
As shown in Figure 6, iNOS protein staining            
was observed in cardiomyocytes of cirrhotic rats. The 
 
Table 1. Ventricular TNF-α levels and plasma concentration of nitrite 
in the studied groups 
 
Values are expressed as mean±SEM (n=6 in each group), aP<0.001 vs 
Control, bP<0.01 vs CCl4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Immunohistochemical staining of iNOS protein. In the 
cirrhotic hearts, iNOS-positive cells are localized in cardiomyocytes. 
No markedly immunostaining is observable on the slide resulted from 
control and minocycline-treated groups. Note the increased 
immunostaining of iNOS in the myocytes of the rats with cirrhosis, as 
well as, CCl4+tetracycline group. In contrast, treatment with 
minocycline caused a decreased significantly iNOS immunostaining in 
ventricles isolated from cirrhotic rats. (Original magnification 40×) 
 
results showed significant increase of iNOS protein 
expression in cirrhotic heart in comparison with 
control and minocycline-treated ones. 
A representative immunohistochemical localization 
of iNOS protein in ventricles of all experimental groups 
is shown in Figure 6A decreased in iNOS 
immunostaining was observed in CCl4+minocycline 
hearts in comparison with cirrhotic hearts (Figure 6D). 
These data were consistent with the results of Western 
blot assay, confirming decreased iNOS protein 
expression in CCl4+minocycline hearts compared to 
cirrhotic ones (Figure 7). On the other hand, there were 
no significant differences in iNOS protein expression 
and localization between CCl4 and CCl4+tetracycline 
hearts (Figures 6E, 7). 
 
 
 
 
Figure 7. Western blot analysis of iNOS protein expression in hearts. 
Optical densitometry showed a significant difference between controls 
and CCl4-induced cirrhotic rats (***P<0.001). Significant decrease of 
optical densitometry of iNOS protein expression in heart isolated from 
minocycline- and CCl4+minocycline- groups compared to CCl4-induced 
cirrhotic rats (###P<0.001, n=4) 
Name Source Control CCl4 Mino CCl4+mino CCl4+tetra 
TNF-α (pg/mg protein) heart 186±31 267±36a 178±31 206±31b 243±34a 
Nitrite (µmoL/L) plasma 40±3 73±6a 35±4 49±3b 64±4a 
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Discussion 
We evaluated the protective effects of minocycline 
in the rat model of CCl4-induced cirrhotic cardio-
myopathy and also determined the possible 
involvement of nitric oxide pathway in the activity of 
minocycline. In this investigation, the isolated papillary 
muscle contractility in response to isoproterenol 
stimulation was significantly impaired in CCl4-induced 
cirrhotic rats, which was consistent with previous 
findings from bile duct-ligated (BDL) animals (8).  
The results demonstrated that the inhibition of the 
myocardial NO synthesis by the minocycline reverses 
the impaired left ventricular papillary muscle contrac-
tility response to isoproterenol, and also shortens the 
prolonged QTc in rats with cirrhosis. This finding is               
in agreement with minocycline effect on ECG in 
cirrhotic rats. Minocycline normalized the prolong QTc 
interval in cirrhotic rats. In addition, incubation with 
either L-NAME, non-selective NOS inhibitor, or AG,                   
selective iNOS inhibitor, normalized the contractile 
responsiveness of the isolated papillary muscles                      
to isoproterenol stimulation in minocycline-treated rats 
with cirrhosis. Our results showed a marked 
correlation between cardiac contractility, serum nitrite 
levels, ventricular level of TNF-α and iNOS expression 
in the studied groups. NO is produced in endothelial 
cells and cardiac myocytes, modulating cardiac 
contractility (7). Also, NO overproduction seems to play 
an important role in pathophysiology of cardiovascular 
complications in cirrhosis (8, 31). Therefore, the ability 
of minocycline to inhibit iNOS expression makes a 
potential of the improvement of cardiac contractility in 
cirrhosis. This was confirmed by treatment of the 
cirrhotic rats with minocycline for an 8-week period. 
These findings provide an evidence for the role of 
minocycline in reduction of NO and subsequent 
increasing the responsiveness of papillary muscles to β-
adrenoceptor stimulation following cirrhosis. These 
findings were strengthened by observation of enhanced 
inotropic responsiveness to isoproterenol stimulation 
following incubation of the isolated papillary muscles 
with either L-NAME or AG. 
The proposed mechanism underlying the effect of 
minocycline on cardiac contractility by decreasing NO 
synthesis is presented as a schematic diagram in Figure 
8. In the current study, the increased serum levels                   
of NO metabolites, as cardio-depressant substances, in 
CCl4-induced cirrhotic rats were reduced by 
minocycline. It seems that Inhibitory effect of 
minocycline on NO production is associated with a 
cGMP-mediated inhibition of voltage-dependent Ca+2 
current, leading to inhibition of phosphodiesterase in 
the heart. This causes a reduced cAMP degradation or 
phosphorylation of cGMP-dependent protein kinase 
(PKG), resulting in an increased influx of calcium via     
L-type Ca+2 channel or release of calcium from 
intracellular sarcoplasmic reticulum. Ultimately,     
actin myosin cross linking is activated to improve the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Schematic of potential mechanisms underlying the positive 
inotropic effect of minocycline in cirrhotic myocyte. The increased 
contractility via accelerated calcium release of cardiac L-type voltage 
dependent ca+2 channels or sarcoplasmic reticulum at cardiac 
myocytes is a downstream of blocked iNOS with minocycline in 
cirrhosis 
 
myocardial contractility in cirrhotic heart (7, 32, 33). 
Minocycline is a potent antibiotic highly effective in 
wide spectrum of pathologies. Minocycline has been 
found to exert various other biological effects in 
addition to its antimicrobial activity. In our current 
results, the effects were found to be associated with the 
inhibition of inducible nitric oxide synthase (17). Also, 
minocycline can inhibit cell death by reducing both 
proapoptotic and proinflamatory mediators. A recent 
pilot study conducted in sixteen patients with chronic 
cholestatic liver disease showed that minocycline in 
twice daily dose of 100 mg orally for one year is well 
tolerated and has potential beneficial effect on chronic 
cholestatic liver complications (23). 
 Based on our current data, we found that changes 
of ventricular NO synthase by minocycline occurs; 
therefore it might be the target for minocycline in terms 
of its ameliorating effect on cirrhotic cardiomyopathy. 
On the other hand, liver cirrhosis leads to 
hemodynamic disorders, such as increased resistance 
to portal blood flow. The increased hepatic resistance is 
resulted from the contraction of myofibroblasts in 
portal hypertensive condition. This hepatic endothelial 
dysfunction can be partly attributed to modulate NO 
bioavailability in the intrahepatic microcirculation. In 
addition, lower sensitivity of hepatic stellate cells 
(HSCS) may cause the activation of HSC, liver sinusoidal 
vasoconstriction, and subsequent increased hepatic 
resistance tone and portal hypertension (34, 35). Our 
data on the role of nitric oxide in portal pressure have 
shown that inhibition of NO production by minocycline 
may play an essential role in the improvement of portal 
hypertension induced by liver cirrhosis. The results 
presented herein support the potential of NO to induce 
portal hypertension, which can be controlled by 
minocycline.  
Moreover, the elevated tissue levels of the cytokines 
including TNF-α and IL-1β along with cardiac 
contractility is contributed to the overproduction of NO, 
a negative inotropic agent, via stimulation of iNOS in 
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cirrhosis (7, 36, 37). Liu et al demonstrated that the 
reduced isoproterenol-stimulated inotropic effect in the 
cirrhotic heart may be attributed to cytokine-induced 
stimulation of iNOS (8). several studies have shown that 
the increased NO synthesis in cirrhotic cardiac tissue is 
associated with the elevated TNF-α level (8, 38). We 
showed that minocycline decreases the enhanced level 
of TNF-α, resulting in a normal inotropic effect of 
cirrhotic papillary muscles. This effect is believed to be 
mediated by a NO-dependent mechanism. 
The present investigation has also demonstrated   
an increased cardiac iNOS protein expression                   
in cirrhotic heart. Our data was consistent with the 
clinical and pre-clinical examinations on patients      
with different cardiomyopathic states (8, 39, 40). The 
immunohistochemistry, as well as, western blot 
technique confirmed the hypothesis that distribution of 
iNOS in the ventricles of CCl4-induced cirrhotic rats and 
its localization in cardiomyocytes are increased. In 
association to some common effects of both drugs, 
Tetracycline lacks the effect to inhibit nitric oxide 
synthesis as shown by our treated group. While, in 
addition to its antibacterial property, minocycline also 
exerts inhibitory effect on nitric oxide synthesis. This is 
the main distinctive effect which we reported in our 
current study. 
Cardioprotective effect of minocycline has been 
reported to decrease the infarct size, as a marker of 
heart damage, in cardiomyocyte culture (20-22). Our 
study suggests that treatment of cirrhotic rats with 
minocycline may results in an increased cardiac 
contractility in response to isoproterenol and 
normalizes portal pressure by inhibiting NO 
production. All these results strongly support the 
findings of Liu et al and Van Obbergh et al that an NO-
dependent pathway is a contributed to the 
pathogenesis of cirrhotic cardiomyopathy (6, 8). The 
experimental study has demonstrated the critical role 
of minocycline in the improvement of cardiac 
dysfunction in CCl4-induced cirrhosis. 
 
Conclusion  
The present study has provided evidence that 
inhibition of nitric oxide synthesis may attenuate the 
liver cirrhosis-induced cardiac contractile dysfunction. 
Therefore, minocycline can exert protective effects                 
on cirrhotic cardiomyopathy by reducing the NO 
production. In conclusion, our findings may open a new 
avenue to find novel indications for minocycline as a 
good candidate drug for treatment or management of 
patients with cirrhotic cardiomyopathy in future. 
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